Company intelligence / Profile preview
Fimbrion Therapeutics
Saint Louis, Missouri, United Statesfimbrion.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Fimbrion has an oral antibacterial co-developed with GSK that has entered Phase I clinical trials. The company is also developing novel therapeutics to combat tuberculosis with Phase II SBIR funding.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecule drugChemical drugs
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
GSK Plc
Beyond the preview
Go deeper on Fimbrion Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fimbrion Therapeutics.